Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis:a Case Report025B3;

doi:10.1016/S1001-9294(13)60036-X

Chinese Medical Sciences Journal ›› 2013, Vol. 28 ›› Issue (2): 127-128.doi: 10.1016/S1001-9294(13)60036-X

• Case Report • Previous Articles

Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis:a Case Report^025B3;

Jing Xie¹, Xiang Zhang¹, Bao-zhi Fang¹, Guang-sheng He^{1, *}, Yun Zhao², De-pei Wu¹

¹Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, ²Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China

Revised:2012-10-22 Published:2013-06-26 Online:2013-06-26
Contact: 0002A;CorrespondingauthorTel/Fax:86-512-65113556,E-mail:heguangsheng@medmail.com.cn

Abstract

Jing Xie, Xiang Zhang, Bao-zhi Fang, Guang-sheng He, Yun Zhao, De-pei Wu. Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis:a Case Report^025B3;[J].Chinese Medical Sciences Journal, 2013, 28(2): 127-128.

References 10

1.	Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
2.	Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006:57:145-64.
3.	Burchert A, Wang Y, Cai D,et al. Compensatory PI3- kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005;19:1774-82.
4.	Barnes DJ, Melo JV. Management of chronic myeloid leukemia:targets for molecular therapy. Semin Hematol 2003;40:34-49.
5.	Hidalgo M, Rowinsky EK. The rapamycin-sensitive transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6.
6.	Podsypanina K, Lee RT, Politis C,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten0002B;/- mice. Proc Natl Acad Sci U S A 2001;98:10320-5.
7.	Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T,et al. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin- dependent kinase inhibitors. Exp Hematol 2001;29:582-8.
8.	Ly C, Arechiga AF, Melo JV,et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716-22.
9.	Mohi MG, Boulton C, Gu TL,et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. PNAS 2004;101:3130-5.
10	Mayerhofer M, Boehm A, Aichberger KJ,et al. In vitro and in vivo antileukemic effects of the mTOR-targeting drugs rapamycin in patients with imatinib-resistant CML. Blood 2005;106:abstract4834.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis:a Case Report^025B3;

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 10

Related Articles 0

Metrics

Recommended 10